Lyndra

Clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing long-acting oral therapies. Utilizing its proprietary LYNX™ drug delivery platform, the company aims to transform standard oral medications into weekly or monthly doses, potentially improving patient adherence and outcomes. The primary beneficiaries of Lyndra Therapeutics' innovations are patients requiring consistent medication regimens, healthcare providers, and the broader pharmaceutical industry.